Search

Displaying results 641 - 650 of 5895 in total
  1. Drug

    Chikungunya vaccine (live, attenuated)

    go.drugbank.com/drugs/DB18701
    ApprovedInvestigational

    [L48726] It is approved for use in patients 18 years of age and older who are at high-risk of exposure to chikungunya virus. … In late 2013, the first cases were identified in the Caribbean, and it has since spread to most of the Americas.[L48786] There are no approved treatments for active chikungunya virus infection.

  2. Drug

    Cabotegravir

    go.drugbank.com/drugs/DB11751
    ApprovedInvestigational

    [A227668,L31193] Cabotegravir was granted FDA approval on 21 January 2021 in combination with rilpivirine to treat HIV-1 infection in virologically suppressed individuals. … [L31198] While previously administered once monthly only, this combination product was granted FDA approval for dosing every two months on February 01, 2022 [L40084] and without the need for an oral lead-in

  3. Drug

    Crizanlizumab

    go.drugbank.com/drugs/DB15271
    ApprovedInvestigational

    [A187904] Though hydroxyurea has been shown to reduce the frequency of vaso-occlusive crises, adherence to this therapy is difficult due to adverse effects and the high variability of response to the drug … Crizanlizumab is a humanized IgG2 monoclonal antibody used to reduce the frequency of vaso-occlusive crises in patients with sickle cell disease.

  4. Drug

    Dutasteride

    go.drugbank.com/drugs/DB01126
    ApprovedInvestigational

    Its clinical efficacy against benign prostate hyperplasia in male patients is comparable to that of [finasteride], a specific type II 5α-reductase inhibitor. … Dutasteride was approved by the FDA in 2001 for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men as monotherapy or in combination with the α-adrenergic antagonist [tamsulosin] to

    Products: DUTASTERIDE DOC GENERICI
  5. Drug

    Sildenafil

    go.drugbank.com/drugs/DB00203
    ApprovedInvestigational

    The result of doing so allows cGMP present in both the penis and pulmonary vasculature to elicit smooth muscle relaxation and vasodilation that subsequently facilitates relief in pulmonary arterial hypertension … Interestingly enough, it is precisely via this mechanism why sildenafil was at first researched as a potential treatment for angina - or chest pain associated with inadequate blood flow to the heart -

    Products: GO, SILDENAFIL DOC GENERICI
  6. Drug

    Bosentan

    go.drugbank.com/drugs/DB00559
    ApprovedInvestigational

    Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure.

    Synonyms: p-tert-Butyl-N-(6-(2-hydroxyethoxy)-5-(o-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl)benzenesulfonamide
  7. Drug

    Ixekizumab

    go.drugbank.com/drugs/DB11569
    ApprovedInvestigational

    It is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. … Ixekizumab is comprised of two identical light chain polypeptides of 219 amino acids each and two identical heavy chain polypeptides of 445 amino acids each, and has a molecular weight of 146,158 Daltons

  8. Drug

    Eftrenonacog alfa

    go.drugbank.com/drugs/DB11608
    Approved

    It is an X-linked genetic disease caused by mutation of the gene for coagulation protein factor IX (FIX), leading to decreased levels of endogenous factor IX and increased susceptibility to recurrent bleeding … Eftrenonacog alfa acts as a replacement therapy to restore the levels of factor IX and allow normal hemostasis.

  9. Drug

    Trolamine

    go.drugbank.com/drugs/DB13747
    ApprovedInvestigational

    Trolamine, which is also referred to as triethanolamine (TEA), is a tertiary amine and a triol. It is a bifunctional compound that exhibits both properties of alcohols and amines.

  10. Drug

    Hydromorphone

    go.drugbank.com/drugs/DB00327
    ApprovedIllicitInvestigational

    Due to these modifications, it presents a very high potency and comparable side effect profile to the parent compound. … Structurally, hydromorphone derived from [morphine] in the modification of the hydroxyl group in the carbon 6 to a carbonyl and the absence of a double bond between the carbon 7 and 8.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSynonyms: 4,5-Epoxy-3-hydroxy-17-methylmorphinan-6-one, (-)-(5R)-4,5-Epoxy-3-hydroxy-9α-methylmorphinan-6-one